03.07.2024 / Deals & Cases

Deal: Wenger Vieli advised Privilege Ventures on its funding in Enantios

Wenger Vieli advised Privilege Ventures, a Swiss venture capital firm, on all Swiss legal aspects concerning its investment in Enantios. The CHF 1.8 Mio funding round was led by Privilege Ventures and also included other investors. This strategic investment underscores Privilege Ventures' commitment to fostering innovation in Enantios' cutting-edge technology aimed at eliminating critical bottlenecks in traditional therapeutic development.

Enantios, a pioneering company in computational therapeutic design, leverages advanced AI algorithms to revolutionize medical R&D. Founded by experts from ETH Zurich, the company specializes in accelerating therapeutic discovery processes to enhance treatment efficacy and reduce time-to-market for new treatments. The investment will boost Enantios' mission to expand its computational platform and advance its innovative pipeline.

The team was led by Michael Baier (Partner, Venture Capital/M&A) together with Michèle Joho-Menotti (Senior Associate, Corporate/M&A)